查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1954669

全球藥物洗脫球囊導管市場：市場規模、佔有率、成長率、產業分析、依類型、應用和地區劃分的分析以及未來預測（2026-2034）

Drug-eluting Balloon Catheters Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 124 Pages | 商品交期: 請詢問到貨日

價格

藥物洗脫球囊導管市場成長驅動因子

2025年全球藥物洗脫球囊導管市場規模為7.7805億美元，預計2026年將達到8.4634億美元。最終，預計到2034年將成長至20.5326億美元，2026年至2034年的複合年增長率（CAGR）將達到11.72%。市場成長的主要驅動因素包括心血管疾病盛行率的上升、微創手術的日益普及以及藥物洗脫球囊導管（DEBC）相對於傳統藥物洗脫支架（DES）的優勢。

藥物洗脫球囊導管（也稱為藥物塗層球囊導管）是一種先進的醫療器械，它透過充氣球囊將抗增殖藥物直接輸送到血管壁。這種標靶給藥方式可以恢復血管腔內的血管生成，治療動脈粥狀硬化和支架內再狹窄，並降低延遲血栓形成的風險，且無需植入永久性裝置。該技術能夠促進血管壁快速癒合，並抑制平滑肌細胞增殖，因此與藥物洗脫支架（DES）相比，它是一種更安全的選擇。

市場區隔及主要驅動因素

依藥物類型劃分，紫杉醇類藥物將在2026年佔市場主導地位，市佔率高達93.72%，市場規模達7.9316億美元。紫杉醇洗脫球囊導管已確立了穩固的市場地位，新產品的不斷推出也持續推動該細分市場的成長。 由於西羅莫司對與動脈粥狀硬化相關的缺氧細胞具有強大的抗增殖作用，因此預計該細分市場將實現顯著的複合年增長率 (CAGR)，使其適用於治療血管再狹窄。

依適應症劃分，預計到 2026 年，週邊血管介入治療細分市場將佔總市場的 76.00%，達到 6.4324 億美元。這主要得益於週邊動脈疾病 (PAD) 盛行率的上升以及針對性產品的上市。冠狀動脈介入治療細分市場預計將以最高的複合年增長率成長，這主要得益於波士頓科學公司紫杉醇塗層 PTCA 球囊導管在日本的臨床試驗和新產品獲批。

依終端用戶劃分，預計到 2026 年，醫院和門診手術中心 (ASC) 將佔最大的市場佔有率（66.32%，5.613 億美元）。這主要歸因於醫院支出的增加以及患者尋求全面診斷和治療的趨勢。此外，隨著導管介入治療設施的增加，冠狀動脈和周邊血管治療的可近性正在擴大，專科診所和導管介入實驗室的數量也將顯著增加。

區域趨勢

北美將在2025年引領全球市場，佔48.84%的市佔率（總計3.8004億美元）。這主要歸功於週邊動脈疾病（PAD）和冠狀動脈疾病（CAD）的高發病率、技術進步以及美敦力（Medtronic）和BD等大型企業的存在。預計到2026年，美國市場規模將達到3.8195億美元，PAD患者人數預計將達800萬至1200萬人。

歐洲市場也保持著強勁的地位，德國、法國和英國憑藉其先進的醫療基礎設施和不斷增長的血管疾病病例，做出了重要貢獻。 預計2026年，英國市場規模將達到3,631萬美元，德國市場規模預計將達到5,878萬美元。

亞太市場預計將以最高的複合年增長率成長，這主要得益於患者對微創手術的偏好日益增強以及週邊動脈疾病（PAD）盛行率的上升。預計到2026年，日本、中國和印度的市場規模將分別達到4,138萬美元、4,449萬美元和1,937萬美元。巴西和墨西哥等拉丁美洲國家的PAD病例正在增加，並且獲得先進治療的機會也在增加。儘管仍存在監管方面的挑戰，但中東和非洲地區的市場正在逐步普及。

產業主要參與者及趨勢

主要市場參與者包括美敦力 (Medtronic)、BD、B. Brown SE、波士頓科學公司 (Boston Scientific Corporation)、飛利浦 (Philips)、微創醫療 (Microport Medical (Group) Inc.)、美林生命科學 (Merrill Life Sciences)、百多力 (Biotronic) 和 Cordis。每家公司都專注於研發和新產品發布，以擴大市場佔有率。主要進展如下：

  • 2022年8月：BD啟動了首個週邊西羅莫司藥物洗脫球囊的人體臨床試驗，以驗證其治療週邊動脈疾病 (PAD) 的有效性。
  • 2021年1月：微創醫療的Reewarm PTX DCB PTA導管獲得歐盟CE認證，用於股膕動脈介入治療。
  • 2020年11月：波士頓科學的Ranger DCB獲得FDA批准，用於治療PAD、股淺動脈 (SFA) 和膕動脈 (PPA)。
  • 2019年10月：飛利浦的低劑量藥物塗層球囊（DCB）產品Stellarex獲得FDA核准。
  • 2017年6月：飛利浦收購Spectranetics以加強其DCB產品線。

市場限制因子

儘管市場呈現成長趨勢，但藥物塗層球囊（DEBC）的推廣應用仍面臨挑戰。研究表明，在股膕動脈中使用紫杉醇塗層球囊有較高的死亡風險，可能會限制其應用。美敦力已就其IN.PACT AV DCB相關的延遲死亡風險發出警告。 此外，嚴格的監管，特別是美國FDA批准的冠狀動脈藥物交換器（DEBC）短缺，可能會阻礙市場擴張。

新冠疫情的影響

疫情暫時降低了需求，導致2020年全球收入下降13.7%。這主要是由於血管成形術數量的減少。波士頓科學公司介入心臟病部門2020年的收入下降了18.4%。 2021年，隨著限制措施的放寬和手術的恢復，市場開始復甦，全球對DEBC的需求也在增加。

目錄

第一章：引言

第二章：摘要整理

第三章：市場動態

  • 市場驅動因素
  • 市場限制因素
  • 市場機遇
  • 市場趨勢

第四章：主要發現

  • 週邊動脈疾病 (PAD) 盛行率：區域分佈（2025 年）
  • 在開發產品分析
  • 新產品發布
  • 主要行業趨勢
  • 新冠疫情對市場的影響

第五章 全球藥物洗脫球囊導管市場分析：洞察與預測 （2021-2034）

  • 市場分析、洞察與預測：依藥物分類
    • 紫杉醇
    • 西羅莫司
    • 其他
  • 市場分析、洞察與預測：依適應症分類
    • 冠狀動脈介入治療
    • 週邊血管介入治療
  • 市場分析、洞察與預測：依最終用戶分類
    • 醫院及門診手術中心
    • 專科診所及導管室
  • 市場分析、洞察與預測：依地區分類
    • 北美
    • 歐洲
    • 亞太地區
    • 其他地區（ROW）

第六章 北美藥物洗脫球囊導管市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • 美國
    • 加拿大

第七章 歐洲藥物洗脫球囊導管市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • 英國
    • 德國
    • 法國
    • 西班牙
    • 義大利
    • 斯堪的納維亞
    • 其他歐洲地區

第八章 亞太地區藥物洗脫球囊導管市場分析：洞察與預測（2021-2034）

  • 國家細分市場
    • 日本
    • 中國
    • 印度
    • 澳大利亞
    • 東南亞
    • 其他亞太地區

第九章 其他地區（ROW）藥物洗脫球囊導管市場分析：洞察與預測（2021-2034）

第10章 競爭分析

  • 全球市場佔有率分析(2025年)
  • 企業簡介
    • Medtronic
    • Koninklijke Philips N.V.
    • Boston Scientific Corporation
    • BD
    • B. Braun SE
    • Meril Life Sciences Pvt. Ltd.
    • BIOTRONIK
    • Cordis
    • MicroPort Medical(Group)Co., Ltd.
Product Code: FBI107028

Growth Factors of drug-eluting balloon catheters Market

The global drug-eluting balloon catheters market was valued at USD 778.05 million in 2025 and is projected to reach USD 846.34 million in 2026, eventually growing to USD 2,053.26 million by 2034, representing a robust CAGR of 11.72% during 2026-2034. The market's growth is primarily driven by the rising prevalence of cardiovascular diseases, increasing adoption of minimally invasive procedures, and the advantages of drug-eluting balloon catheters (DEBCs) over traditional drug-eluting stents (DES).

Drug-eluting balloon catheters, also known as drug-coated balloon catheters, are advanced devices that deliver anti-proliferative drugs directly into the vessel wall via inflated balloons. This targeted drug delivery restores luminal vascularity, treats atherosclerosis and in-stent restenosis, and reduces the risk of late thrombosis without leaving a permanent implant. The technology supports rapid healing of the vessel wall and prevents smooth muscle cell proliferation, positioning it as a safer alternative to DES.

Market Segmentation and Key Drivers

By drug type, the paclitaxel segment dominated the market in 2026, accounting for 93.72% of the market with a size of USD 793.16 million. Paclitaxel-eluting balloon catheters have a well-established presence, and the launch of new products continues to drive segment growth. The sirolimus segment is expected to witness a significant CAGR due to its stronger anti-proliferative effect on atherosclerosis-related hypoxic cells, making it suitable for treating vascular restenosis.

In terms of indication, the peripheral intervention segment accounted for 76.00% of the market in 2026, valued at USD 643.24 million, driven by the growing prevalence of peripheral artery disease (PAD) and targeted product launches. The coronary intervention segment is expected to grow at the fastest CAGR, with clinical trials and new product approvals, such as Boston Scientific's Agent paclitaxel-coated PTCA balloon catheter trial in Japan, contributing to growth.

By end-user, hospitals and ambulatory surgical centers (ASCs) held the largest share in 2026, contributing 66.32% of the market (USD 561.3 million), due to higher hospital expenditure and patient preference for comprehensive diagnosis and treatment. Specialty clinics and catheterization laboratories are also expected to expand significantly as more catheterization facilities increase accessibility to coronary and peripheral vascular procedures.

Regional Insights

North America dominated the global market in 2025 with a 48.84% share, totaling USD 380.04 million, due to high PAD and coronary artery disease (CAD) prevalence, technological advancements, and presence of key players like Medtronic and BD. The U.S. market is projected to reach USD 381.95 million by 2026, with 8-12 million people affected by PAD.

Europe also holds a strong position, with Germany, France, and the U.K. contributing significantly due to advanced healthcare infrastructure and rising vascular disease cases. The UK market is projected to reach USD 36.31 million by 2026, while Germany is expected to reach USD 58.78 million.

The Asia Pacific market is projected to grow at the fastest CAGR, driven by increasing patient preference for minimally invasive procedures and rising PAD prevalence. Japan, China, and India are expected to reach USD 41.38 million, USD 44.49 million, and USD 19.37 million, respectively, by 2026. Latin American countries like Brazil and Mexico are witnessing rising PAD cases and improved access to advanced interventions. Gradual adoption is observed in the Middle East & Africa, though regulatory hurdles persist.

Industry Players and Developments

Prominent market players include Medtronic, BD, B. Braun SE, Boston Scientific Corporation, Koninklijke Philips N.V., MicroPort Medical (Group) Co., Ltd., Meril Life Sciences Pvt. Ltd., BIOTRONIK, and Cordis. Companies focus on R&D and new product launches to expand market presence. Notable developments include:

  • August 2022: BD launched a first-in-human trial of a peripheral sirolimus drug-coated balloon to study PAD treatment efficacy.
  • January 2021: MicroPort received EU CE mark for Reewarm PTX DCB PTA catheter for femoral popliteal artery interventions.
  • November 2020: Boston Scientific obtained FDA approval for Ranger DCB to treat PAD, SFA, and PPA.
  • October 2019: Philips received FDA approval for Stellarex low-dose DCBs.
  • June 2017: Philips acquired Spectranetics to enhance its DCB portfolio.

Market Restraints

Despite growth, DEBC adoption faces challenges. Studies highlight high mortality risks with paclitaxel-coated balloons in femoropopliteal arteries, potentially limiting adoption. Medtronic has issued warnings regarding late mortality risks with its IN.PACT AV DCB. Additionally, stringent regulations-particularly the lack of FDA-approved coronary DEBCs in the U.S.-may hinder market expansion.

COVID-19 Impact

The pandemic temporarily reduced demand, with global revenues declining by -13.7% in 2020 due to fewer angioplasty procedures. Boston Scientific experienced an 18.4% revenue drop in interventional cardiology in 2020. Recovery began in 2021 with eased restrictions and resumed procedures, increasing DEBC demand globally.

Conclusion

The drug-eluting balloon catheters market is poised for strong growth from USD 778.05 million in 2025 to USD 2,053.26 million by 2034, driven by rising heart disease prevalence, technological advancements, minimally invasive interventions, and product innovation. While regulatory challenges and safety concerns exist, the market's expansion, particularly in North America and Asia Pacific, signals a promising future for DEBC adoption worldwide.

Segmentation By Drug

  • Paclitaxel
  • Sirolimus
  • Others

By Indication

  • Coronary Intervention
  • Peripheral Intervention

By End-user

  • Hospitals & ASCs
  • Specialty Clinics and Catheterization Laboratories

By Geography

  • North America (U.S. and Canada)
  • Europe (U.K., Germany, France, Italy, Spain, Scandinavia, and Rest of Europe)
  • Asia Pacific (Japan, China, India, Australia, Southeast Asia, and Rest of Asia Pacific)
  • Rest of the World

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Prevalence of Peripheral Artery Disease (PAD), in 2025 - By Region
  • 4.2. Pipeline Analysis
  • 4.3. New Product Launches
  • 4.4. Key Industry Developments
  • 4.5. Impact of COVID-19 on the Market

5. Global Drug-eluting Balloon Catheters Market Analysis, Insights and Forecast, 2025-2034

  • 5.1. Market Analysis, Insights and Forecast - By Drug
    • 5.1.1. Paclitaxel
    • 5.1.2. Sirolimus
    • 5.1.3. Others
  • 5.2. Market Analysis, Insights and Forecast - By Indication
    • 5.2.1. Coronary intervention
    • 5.2.2. Peripheral intervention
  • 5.3. Market Analysis, Insights and Forecast - By End-user
    • 5.3.1. Hospitals & ASCs
    • 5.3.2. Specialty Clinics and Catheterization Laboratories
  • 5.4. Market Analysis, Insights and Forecast - By Region
    • 5.4.1. North America
    • 5.4.2. Europe
    • 5.4.3. Asia Pacific
    • 5.4.4. Rest of the World

6. North America Drug-eluting Balloon Catheters Market Analysis, Insights and Forecast, 2025-2034

  • 6.1. Market Analysis, Insights and Forecast - By Drug
    • 6.1.1. Paclitaxel
    • 6.1.2. Sirolimus
    • 6.1.3. Others
  • 6.2. Market Analysis, Insights and Forecast - By Indication
    • 6.2.1. Coronary intervention
    • 6.2.2. Peripheral intervention
  • 6.3. Market Analysis, Insights and Forecast - By End-user
    • 6.3.1. Hospitals & ASCs
    • 6.3.2. Specialty Clinics and Catheterization Laboratories
  • 6.4. Market Analysis, Insights and Forecast - By Country
    • 6.4.1. U.S.
    • 6.4.2. Canada

7. Europe Drug-eluting Balloon Catheters Market Analysis, Insights and Forecast, 2025-2034

  • 7.1. Market Analysis, Insights and Forecast - By Drug
    • 7.1.1. Paclitaxel
    • 7.1.2. Sirolimus
    • 7.1.3. Others
  • 7.2. Market Analysis, Insights and Forecast - By Indication
    • 7.2.1. Coronary intervention
    • 7.2.2. Peripheral intervention
  • 7.3. Market Analysis, Insights and Forecast - By End-user
    • 7.3.1. Hospitals & ASCs
    • 7.3.2. Specialty Clinics and Catheterization Laboratories
  • 7.4. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 7.4.1. U.K.
    • 7.4.2. Germany
    • 7.4.3. France
    • 7.4.4. Spain
    • 7.4.5. Italy
    • 7.4.6. Scandinavia
    • 7.4.7. Rest of Europe

8. Asia Pacific Drug-eluting Balloon Catheters Market Analysis, Insights and Forecast, 2025-2034

  • 8.1. Market Analysis, Insights and Forecast - By Drug
    • 8.1.1. Paclitaxel
    • 8.1.2. Sirolimus
    • 8.1.3. Others
  • 8.2. Market Analysis, Insights and Forecast - By Indication
    • 8.2.1. Coronary intervention
    • 8.2.2. Peripheral intervention
  • 8.3. Market Analysis, Insights and Forecast - By End-user
    • 8.3.1. Hospitals & ASCs
    • 8.3.2. Specialty Clinics and Catheterization Laboratories
  • 8.4. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 8.4.1. Japan
    • 8.4.2. China
    • 8.4.3. India
    • 8.4.4. Australia
    • 8.4.5. Southeast Asia
    • 8.4.6. Rest of Asia Pacific

9. Rest of the World Drug-eluting Balloon Catheters Market Analysis, Insights and Forecast, 2025-2034

  • 9.1. Market Analysis, Insights and Forecast - By Drug
    • 9.1.1. Paclitaxel
    • 9.1.2. Sirolimus
    • 9.1.3. Others
  • 9.2. Market Analysis, Insights and Forecast - By Indication
    • 9.2.1. Coronary intervention
    • 9.2.2. Peripheral intervention
  • 9.3. Market Analysis, Insights and Forecast - By End-user
    • 9.3.1. Hospitals & ASCs
    • 9.3.2. Specialty Clinics and Catheterization Laboratories

10. Competitive Analysis

  • 10.1. Global Market Share Analysis (2025)
  • 10.2. Company Profiles (Overview, Product, SWOT Analysis, Recent Developments, Strategies, financials (Based on Availability))
    • 10.2.1. Medtronic
      • 10.2.1.1. Overview,
      • 10.2.1.2. Product,
      • 10.2.1.3. SWOT Analysis,
      • 10.2.1.4. Recent Developments,
      • 10.2.1.5. Strategies,
      • 10.2.1.6. financials (Based on Availability)
    • 10.2.2. Koninklijke Philips N.V.
      • 10.2.2.1. Overview,
      • 10.2.2.2. Product,
      • 10.2.2.3. SWOT Analysis,
      • 10.2.2.4. Recent Developments,
      • 10.2.2.5. Strategies,
      • 10.2.2.6. financials (Based on Availability)
    • 10.2.3. Boston Scientific Corporation
      • 10.2.3.1. Overview,
      • 10.2.3.2. Product,
      • 10.2.3.3. SWOT Analysis,
      • 10.2.3.4. Recent Developments,
      • 10.2.3.5. Strategies,
      • 10.2.3.6. financials (Based on Availability)
    • 10.2.4. BD
      • 10.2.4.1. Overview,
      • 10.2.4.2. Product,
      • 10.2.4.3. SWOT Analysis,
      • 10.2.4.4. Recent Developments,
      • 10.2.4.5. Strategies,
      • 10.2.4.6. financials (Based on Availability)
    • 10.2.5. B. Braun SE
      • 10.2.5.1. Overview,
      • 10.2.5.2. Product,
      • 10.2.5.3. SWOT Analysis,
      • 10.2.5.4. Recent Developments,
      • 10.2.5.5. Strategies,
      • 10.2.5.6. financials (Based on Availability)
    • 10.2.6. Meril Life Sciences Pvt. Ltd.
      • 10.2.6.1. Overview,
      • 10.2.6.2. Product,
      • 10.2.6.3. SWOT Analysis,
      • 10.2.6.4. Recent Developments,
      • 10.2.6.5. Strategies,
      • 10.2.6.6. financials (Based on Availability)
    • 10.2.7. BIOTRONIK
      • 10.2.7.1. Overview,
      • 10.2.7.2. Product,
      • 10.2.7.3. SWOT Analysis,
      • 10.2.7.4. Recent Developments,
      • 10.2.7.5. Strategies,
      • 10.2.7.6. financials (Based on Availability)
    • 10.2.8. Cordis
      • 10.2.8.1. Overview,
      • 10.2.8.2. Product,
      • 10.2.8.3. SWOT Analysis,
      • 10.2.8.4. Recent Developments,
      • 10.2.8.5. Strategies,
      • 10.2.8.6. financials (Based on Availability)
    • 10.2.9. MicroPort Medical (Group) Co., Ltd.
      • 10.2.9.1. Overview,
      • 10.2.9.2. Product,
      • 10.2.9.3. SWOT Analysis,
      • 10.2.9.4. Recent Developments,
      • 10.2.9.5. Strategies,
      • 10.2.9.6. financials (Based on Availability)

List of Tables

  • Table 01: Global Drug-eluting Balloon Catheters Market Revenue (USD million) Forecast, By Drug, 2025-2034
  • Table 02: Global Drug-eluting Balloon Catheters Market Revenue (USD million) Forecast, By Indication, 2025-2034
  • Table 03: Global Drug-eluting Balloon Catheters Market Revenue (USD million) Forecast, By End-user, 2025-2034
  • Table 04: Global Drug-eluting Balloon Catheters Market Revenue (USD million) Forecast, By Region, 2025-2034
  • Table 05: North America Drug-eluting Balloon Catheters Market Revenue (USD million) Forecast, By Drug, 2025-2034

North America Market Analysis and Insights, By Indication

  • Figure 08: North America Drug-eluting Balloon Catheters Market Value (USD million), by Indication, 2025 & 2034
  • Figure 09: North America Drug-eluting Balloon Catheters Market Value Share (%), by Indication, 2025
  • Table 06: North America Drug-eluting Balloon Catheters Market Revenue (USD million) Forecast, By Indication, 2025-2034
  • Table 07: North America Drug-eluting Balloon Catheters Market Revenue (USD million) Forecast, By End-user, 2025-2034
  • Table 08: North America Drug-eluting Balloon Catheters Market Revenue (USD million) Forecast, By Country, 2025-2034
  • Table 09: Europe Drug-eluting Balloon Catheters Market Revenue (USD million) Forecast, By Drug, 2025-2034
  • Table 10: Europe Drug-eluting Balloon Catheters Market Revenue (USD million) Forecast, By Indication, 2025-2034
  • Table 11: Europe Drug-eluting Balloon Catheters Market Revenue (USD million) Forecast, By End-user, 2025-2034
  • Table 12: Europe Drug-eluting Balloon Catheters Market Revenue (USD million) Forecast, By Country/Sub-region, 2025-2034
  • Table 13: Asia Pacific Drug-eluting Balloon Catheters Market Revenue (USD million) Forecast, By Drug, 2025-2034
  • Table 14: Asia Pacific Drug-eluting Balloon Catheters Market Revenue (USD million) Forecast, By Indication, 2025-2034
  • Table 15: Asia Pacific Drug-eluting Balloon Catheters Market Revenue (USD million) Forecast, By End-user, 2025-2034
  • Table 16: Asia Pacific Drug-eluting Balloon Catheters Market Revenue (USD million) Forecast, By Country/Sub-region, 2025-2034
  • Table 17: Rest of the World Drug-eluting Balloon Catheters Market Revenue (USD million) Forecast, By Drug, 2025-2034
  • Table 18: Rest of the World Drug-eluting Balloon Catheters Market Revenue (USD million) Forecast, By Indication, 2025-2034
  • Table 19: Rest of the World Drug-eluting Balloon Catheters Market Revenue (USD million) Forecast, By End-user, 2025-2034

List of Figures

  • Figure 01: Global Drug-eluting Balloon Catheters Market Revenue Breakdown (USD million, %) by Region, 2025 & 2034

Analysis

  • Figure 02: Global Drug-eluting Balloon Catheters Market Value Share (%), By Drug, 2025 & 2034
  • Figure 03: Global Drug-eluting Balloon Catheters Market Value Share (%), By Indication, 2025 & 2034
  • Figure 04: Global Drug-eluting Balloon Catheters Market Value Share (%), By End-user, 2025 & 2034
  • Figure 05: Global Drug-eluting Balloon Catheters Market Value Share (%), By Region, 2025 & 2034
  • Figure 06: North America Drug-eluting Balloon Catheters Market Value (USD million), by Drug, 2025 & 2034
  • Figure 07: North America Drug-eluting Balloon Catheters Market Value Share (%), by Drug, 2025
  • Figure 08: North America Drug-eluting Balloon Catheters Market Value (USD million), by Indication, 2025 & 2034
  • Figure 09: North America Drug-eluting Balloon Catheters Market Value Share (%), by Indication, 2025
  • Figure 10: North America Drug-eluting Balloon Catheters Market Value (USD million), by End-user, 2025 & 2034
  • Figure 11: North America Drug-eluting Balloon Catheters Market Value Share (%), by End-user, 2025
  • Figure 12: North America Drug-eluting Balloon Catheters Market Value (USD million), by Country, 2025 & 2034
  • Figure 13: North America Drug-eluting Balloon Catheters Market Value Share (%), by Country, 2025
  • Figure 14: Europe Drug-eluting Balloon Catheters Market Value (USD million), by Drug, 2025 & 2034
  • Figure 15: Europe Drug-eluting Balloon Catheters Market Value Share (%), by Drug, 2025
  • Figure 16: Europe Drug-eluting Balloon Catheters Market Value (USD million), by Indication, 2025 & 2034
  • Figure 17: Europe Drug-eluting Balloon Catheters Market Value Share (%), by Indication, 2025
  • Figure 18: Europe Drug-eluting Balloon Catheters Market Value (USD million), by End-user, 2025 & 2034
  • Figure 19: Europe Drug-eluting Balloon Catheters Market Value Share (%), by End-user, 2025
  • Figure 20: Europe Drug-eluting Balloon Catheters Market Value (USD million), by Country/Sub-region, 2025 & 2034
  • Figure 21: Europe Drug-eluting Balloon Catheters Market Value Share (%), by Country/Sub-region, 2025
  • Figure 22: Asia Pacific Drug-eluting Balloon Catheters Market Value (USD million), by Drug, 2025 & 2034
  • Figure 23: Asia Pacific Drug-eluting Balloon Catheters Market Value Share (%), by Drug, 2025
  • Figure 24: Asia Pacific Drug-eluting Balloon Catheters Market Value (USD million), by Indication, 2025 & 2034
  • Figure 25: Asia Pacific Drug-eluting Balloon Catheters Market Value Share (%), by Indication, 2025
  • Figure 26: Asia Pacific Drug-eluting Balloon Catheters Market Value (USD million), by End-user, 2025 & 2034
  • Figure 27: Asia Pacific Drug-eluting Balloon Catheters Market Value Share (%), by End-user, 2025
  • Figure 28: Asia Pacific Drug-eluting Balloon Catheters Market Value (USD million), by Country/Sub-region, 2025 & 2034
  • Figure 29: Asia Pacific Drug-eluting Balloon Catheters Market Value Share (%), by Country/Sub-region, 2025
  • Figure 30: Rest of the World Drug-eluting Balloon Catheters Market Value (USD million), by Drug, 2025 & 2034
  • Figure 31: Rest of the World Drug-eluting Balloon Catheters Market Value Share (%), by Drug, 2025
  • Figure 32: Rest of the World Drug-eluting Balloon Catheters Market Value (USD million), by Indication, 2025 & 2034
  • Figure 33: Rest of the World Drug-eluting Balloon Catheters Market Value Share (%), by Indication, 2025
  • Figure 34: Rest of the World Drug-eluting Balloon Catheters Market Value (USD million), by End-user, 2025 & 2034
  • Figure 35: Rest of the World Drug-eluting Balloon Catheters Market Value Share (%), by End-user, 2025
  • Figure 36: Global Drug-eluting Balloon Catheters Market Share (%), By Company, 2025

Analysis